Inivata Raises $52.6M For Liquid Biopsy Commercialization
Executive Summary
Inivata has raised $52.6m to support commercialization of its blood test for non-small cell lung cancer (NSCLC) diagnosis.
You may also be interested in...
Big Money Spent On Liquid Biopsy Technology In 2021
Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.
Big Money Spent On Liquid Biopsy Technology In 2021
Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.
NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.